Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rad51

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Rad51. Displaying page 1 of 1.
    EudraCT Number: 2018-001660-29 Sponsor Protocol Number: FAB18 Start Date*: 2019-01-16
    Sponsor Name:Leiden University Medical Center
    Full Title: FAB: Functional Analysis of BRCAness
    Medical condition: Recurrent epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005792-12 Sponsor Protocol Number: GOIRC-06-2020 Start Date*: 2022-04-05
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Medical condition: Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003319-12 Sponsor Protocol Number: ICR-CTSU-2014-10046 Start Date*: 2015-03-27
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Insitute of Cancer Research
    Full Title: Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004055-20 Sponsor Protocol Number: ICR-CTSU/2013/10040 Start Date*: 2014-09-23
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Research
    Full Title: A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223.
    Medical condition: Castrate resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-004575-12 Sponsor Protocol Number: DOMEC Start Date*: 2019-07-05
    Sponsor Name:Leiden University Medical Center
    Full Title: DOMEC - phase II trial of Durvalumab (MEDI4736) and Olaparib in Metastatic/recurrent Endometrial Cancer, a DGOG trial.
    Medical condition: advanced endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004323-72 Sponsor Protocol Number: MedOPP190 Start Date*: 2020-02-05
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor...
    Medical condition: Advanced or metastatic HR-positive/HER2-negative breast cancer in patients harboring either gBRCAms or gBRCAwt and HRD.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    21.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    20.1 10022891 - Investigations 10077481 Human epidermal growth factor receptor negative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003835-31 Sponsor Protocol Number: IB2018-04 Start Date*: 2021-09-28
    Sponsor Name:Institut Bergonié
    Full Title: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study
    Medical condition: Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024190 Leiomyosarcomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002971-17 Sponsor Protocol Number: FG-2018/05 Start Date*: 2019-07-18
    Sponsor Name:Centre Georges-François Leclerc
    Full Title: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous r...
    Medical condition: Patients with the following solid malignancy: • Metastatic breast cancer • Metastatic prostate cancer • Metastatic lung cancer • Metastatic head and neck • Metastatic endometrial cancer • M...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064049 Lung adenocarcinoma metastatic LLT
    20.0 100000004864 10027474 Metastatic LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    20.0 100000004864 10007064 Cancer of endometrium metastatic LLT
    20.0 100000004864 10036947 Prostatic cancer metastatic LLT
    20.0 100000004864 10073040 Metastatic oropharyngeal cancer LLT
    20.1 100000004864 10080007 Clear cell renal cell carcinoma metastatic LLT
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    20.0 100000004864 10074852 Laryngeal squamous cell carcinoma metastatic LLT
    20.0 100000004864 10027478 Metastatic disease LLT
    20.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004269-26 Sponsor Protocol Number: ENGOT-ov24-NSGO Start Date*: 2015-05-22
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit
    Full Title: Niraparib versus niraparib-bevacizumab combination in Women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Part 1: AVANOVA1 - A phase I study to evaluate the saf...
    Medical condition: Women with relapsed platinum-sensitive epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) SE (Completed) NO (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-002077-21 Sponsor Protocol Number: ICR-CTSU/2017/10065 Start Date*: 2019-04-18
    Sponsor Name:The Institute of Cancer Research
    Full Title: PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003832-57 Sponsor Protocol Number: UC-0140/1812 Start Date*: 2019-02-28
    Sponsor Name:UNICANCER
    Full Title: DOLAF- An international multicenter phase I/II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients sele...
    Medical condition: ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072740 Locally advanced breast cancer LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    20.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002080-25 Sponsor Protocol Number: NBG-19-01 Start Date*: 2019-06-26
    Sponsor Name:Skåne University Hospital
    Full Title: A TRANSLATIONAL RANDOMIZED PHASE III STUDY EXPLORING THE EFFECT OF THE ADDITION OF CAPECITABINE TO CARBOPLATINUM BASED CHEMOTHERAPY IN EARLY “TRIPLE NEGATIVE” BREAST CANCER.
    Medical condition: Early triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001744-62 Sponsor Protocol Number: 2018/2727 Start Date*: 2018-11-28
    Sponsor Name:Gustave Roussy
    Full Title: A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repai...
    Medical condition: •Molecularly selected cohorts that harbor DNA repair deficiency: –Non-Small Cell Lung Cancer –Urothelial Bladder Cancer –Metastatic Castration Resistant Prostate Cancer –Others: any histology, exce...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066350 Adenocarcinoma of the gastrooesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:31:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA